{'fraction_non_alphanumeric': 0.05218446601941747, 'fraction_numerical': 0.05946601941747573, 'mean_word_length': 4.574324324324325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The plasma level of sICAM‐1 in the chosen inflammatory dermatoses

We have determined the plasma levels of sICAM‐l in 11 patients with generalized lichen planus, 19 with psoriasis, 10 with acrosderoderma. 4 with mycosis fungoides and 14 patients of the control group. All the investigated groups displayed mean values significantly higher than those of the controls (199.5 ± 97.7 ng/ml), and values in generalized lichen planus subjects were much higher (426.8 ± 145.5 ng/ml) than in those with acrosderoderma (360.8 ± 121.7 ng/ml), psoriasis (356.9 ± 175.6 ng/ml) and mycosis fungoides (329.4 ± 142.3 ng/ml). These data suggest that the level of sICAM‐l in plasma increases during different immunological skin diseases. Soluble ICAM‐I is a sensitive marker of inflammatory states in the course of the investigated diseases.